Showing results (91-100 of 118) with videos related to
Sort By:
Pageof 12
Lung Cancer (Amsterdam, Netherlands)|September 18, 2021
A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632Rintaro Noro, Satoshi Igawa, Akihiro Bessho, et al.JAMA Network Open|May 2, 2023
Efficacy of Olanzapine in Addition to Standard Triplet Antiemetic Therapy for Cisplatin-Based Chemotherapy: A Secondary Analysis of the J-FORCE Randomized Clinical TrialMasakazu Abe, Takuhiro Yamaguchi, Yukiyoshi Fujita, et al.Journal of Pharmaceutical Health Care and Sciences|March 3, 2022
Pharmaceutical intervention for adverse events improves quality of life in patients with cancer undergoing outpatient chemotherapyHironori Fujii, Yukino Ueda, Chiemi Hirose, et al.BMJ Open|December 18, 2020
Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1-4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapyHiroko Minatogawa, Naoki Izawa, Takashi Kawaguchi, et al.Journal of Diabetes Investigation|June 26, 2023
Effectiveness of countermeasure for polypharmacy by multidisciplinary team review in patients with diabetes mellitusShohei Nishida, Takehiro Kato, Yuichi Hayashi, et al.Lung Cancer (Amsterdam, Netherlands)|April 28, 2024
Mirtazapine plus granisetron and dexamethasone for carboplatin-induced nausea and vomiting in patients with thoracic cancers: A prospective multicenter phase II trialHirotoshi Iihara, Masamichi Iwai, Ryo Morita, et al.Journal of Cancer|September 1, 2022
Association between the Co-administration of Histamine H2 Receptor Antagonists and the Effectiveness of Capecitabine in Patients with Colorectal Cancer: Propensity Score AnalysisTomoko Yamazaki, Ryuji Uozumi, Hitoshi Kawazoe, et al.The Oncologist|February 10, 2024
Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast CancerKaori Takahashi, Ryuji Uozumi, Toru Mukohara, et al.The Lancet. Oncology|June 20, 2025
Overall efficacy and safety of olanzapine 5 mg added to triplet antiemetics for an anthracycline-containing regimen in patients with breast cancer: a phase 3, double-blind, randomised, placebo-controlled trialMitsue Saito, Hirotoshi Iihara, Mototsugu Shimokawa, et al.Scientific Reports|April 22, 2022
Proton pump inhibitors affect capecitabine efficacy in patients with stage II-III colorectal cancer: a multicenter retrospective studyYoshiko Kitazume, Hitoshi Kawazoe, Ryuji Uozumi, et al.Pageof 12